[go: up one dir, main page]

WO2007012968A3 - Forme dosifee stable d'un antidepresseur - Google Patents

Forme dosifee stable d'un antidepresseur Download PDF

Info

Publication number
WO2007012968A3
WO2007012968A3 PCT/IB2006/002158 IB2006002158W WO2007012968A3 WO 2007012968 A3 WO2007012968 A3 WO 2007012968A3 IB 2006002158 W IB2006002158 W IB 2006002158W WO 2007012968 A3 WO2007012968 A3 WO 2007012968A3
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
antidepressant
stable dosage
relates
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2006/002158
Other languages
English (en)
Other versions
WO2007012968A2 (fr
Inventor
Viswaprasad Varanasi
Haranatha Babu Balanagu
Hidaytulla Shamshuddin Aga
Kishor Dattatray Deo
Sivakumaran Meenakshisunderam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aurobindo Pharma Ltd
Original Assignee
Aurobindo Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurobindo Pharma Ltd filed Critical Aurobindo Pharma Ltd
Publication of WO2007012968A2 publication Critical patent/WO2007012968A2/fr
Publication of WO2007012968A3 publication Critical patent/WO2007012968A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention se rapporte à une forme dosifiée stable renfermant un composé antidépresseur. Cette invention porte en particulier sur une forme dosifiée solide stable comprenant un semi-hydrate d'hydrochlorure de paroxétine préparée par un procédé de granulation par voie humide utilisant de la lactose.
PCT/IB2006/002158 2005-07-29 2006-07-25 Forme dosifee stable d'un antidepresseur Ceased WO2007012968A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1039CH2005 2005-07-29
IN1039/CHE/2005 2005-07-29

Publications (2)

Publication Number Publication Date
WO2007012968A2 WO2007012968A2 (fr) 2007-02-01
WO2007012968A3 true WO2007012968A3 (fr) 2007-05-31

Family

ID=37683713

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/002158 Ceased WO2007012968A2 (fr) 2005-07-29 2006-07-25 Forme dosifee stable d'un antidepresseur

Country Status (1)

Country Link
WO (1) WO2007012968A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109771381B (zh) * 2017-11-13 2021-02-19 北京福元医药股份有限公司 一种帕罗西汀药物制剂

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102525966B (zh) * 2010-12-13 2016-06-29 江苏万全特创医药生物技术有限公司 一种含有帕罗西汀的片剂及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158230A1 (en) * 2001-12-28 2003-08-21 Rakefet Cohen Stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
WO2004091617A1 (fr) * 2003-04-17 2004-10-28 Glaxo Group Limited Combinaison de paroxetine et de 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2s-phenyl-piperidin-3s-yl)-amine dans le traitement de la depression et/ou de l'anxiete
WO2005034954A2 (fr) * 2003-10-08 2005-04-21 Ranbaxy Laboratories Limited Compositions pharmaceutiques de paroxetine
WO2006023347A1 (fr) * 2004-08-20 2006-03-02 Alpharma, Inc. Formulations à base de paroxétine
US20060216345A1 (en) * 2005-03-24 2006-09-28 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition including paroxetine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158230A1 (en) * 2001-12-28 2003-08-21 Rakefet Cohen Stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
WO2004091617A1 (fr) * 2003-04-17 2004-10-28 Glaxo Group Limited Combinaison de paroxetine et de 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2s-phenyl-piperidin-3s-yl)-amine dans le traitement de la depression et/ou de l'anxiete
WO2005034954A2 (fr) * 2003-10-08 2005-04-21 Ranbaxy Laboratories Limited Compositions pharmaceutiques de paroxetine
WO2006023347A1 (fr) * 2004-08-20 2006-03-02 Alpharma, Inc. Formulations à base de paroxétine
US20060216345A1 (en) * 2005-03-24 2006-09-28 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition including paroxetine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109771381B (zh) * 2017-11-13 2021-02-19 北京福元医药股份有限公司 一种帕罗西汀药物制剂

Also Published As

Publication number Publication date
WO2007012968A2 (fr) 2007-02-01

Similar Documents

Publication Publication Date Title
WO2006065480A3 (fr) Tetrahydrocarbazoles en tant qu'agents actifs permettant d'inhiber la production de vegf par regulation de la traduction
WO2007052289A3 (fr) Nouvelle composition de comprime dispersible
WO2007093627A3 (fr) Composition biocide
EP2460797A3 (fr) Procédé de préparation d'ivabradine hydrochloride
AP2006003522A0 (en) Yd-crystalline form of ivabradine hydrochloride, a process for its preparation adn pharmaceutical compositions containing it.
WO2006074951A3 (fr) Composition d'olanzapine ou de donepezil a desintegration orale
WO2007127292A3 (fr) Formes cristallines de tigecycline et leurs procedes de preparation
WO2010015657A3 (fr) Nouveaux alcoxypyrazoles
ZA200904333B (en) Process for the preparation of 6,6-Dimethyl-3-azabicyclo-[3.1.0]-hexane compounds utilizing bisulfite intermediate
TW200720246A (en) Novel process for the preparation of acid chlorides
TW200621739A (en) Asymmetric synthesis of substituted dihydrobenzofurans
WO2007119114A3 (fr) Procédé perfectionné de synthèse et de préeparations de sels de duloxétine
WO2006087143A8 (fr) Nouveaux procedes de preparation d'un 2h-chromene
WO2008104880A3 (fr) Formes posologiques solides stables d'un antidépresseur
WO2005012227A3 (fr) Procede de preparation de 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenol, un metabolite de la tolterodine
WO2008035360A3 (fr) Nouvelles formes cristallines
WO2010079506A3 (fr) Composition pharmaceutique d'aripiprazole
WO2007023342A3 (fr) Processus de fabrication d'acides bisphosphoniques gemines et de sels et/ou d'hydrates de ceux-ci repondant aux normes pharmaceutiques
WO2006075139A3 (fr) Procede nouveau
WO2007012968A3 (fr) Forme dosifee stable d'un antidepresseur
WO2009013594A3 (fr) Procédé de préparation de compositions solides à libération contrôlée contenant de l'oxcarbazépine, et compositions obtenues par ce procédé
WO2008007391A3 (fr) Procédé amélioré de préparation du valsartan
WO2007132344A3 (fr) Compositions à libération régulée d'un agent antidépresseur
WO2007039076A3 (fr) Composé de niobium
SI2016073T1 (sl) Postopek za pripravo ÄŤistega irbesartana

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06795217

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06795217

Country of ref document: EP

Kind code of ref document: A2